$VRDN
Viridian Therapeutics, Inc.\DE

2020 Q1 Form 10-K Financial Statement

#000159075020000021 Filed on March 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019
Revenue $828.0K $880.0K $4.461M
YoY Change 122.58% 84.87% -46.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.720M $2.530M $11.35M
YoY Change -19.05% -6.3% 2.71%
% of Gross Profit
Research & Development $6.103M $8.417M $34.79M
YoY Change -30.26% 2.22% 14.37%
% of Gross Profit
Depreciation & Amortization $68.00K $70.00K $300.0K
YoY Change -6.85% 0.0% 0.0%
% of Gross Profit
Operating Expenses $8.826M $8.417M $46.44M
YoY Change -27.11% 2.22% 11.98%
Operating Profit -$7.998M -$41.98M
YoY Change -31.85% 26.89%
Interest Expense -$50.00K -$50.00K $110.0K
YoY Change -145.45% -135.71% -71.05%
% of Operating Profit
Other Income/Expense, Net $95.00K -$47.00K $941.0K
YoY Change -71.98% -134.56% -24.96%
Pretax Income -$8.040M -$10.12M -$41.87M
YoY Change -30.87% -1.94% 28.04%
Income Tax
% Of Pretax Income
Net Earnings -$8.044M -$10.12M -$41.87M
YoY Change -30.83% -1.93% 28.04%
Net Earnings / Revenue -971.5% -1149.77% -938.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.653M -$4.685M -$20.03M
COMMON SHARES
Basic Shares Outstanding 53.07M shares 31.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.10M $26.80M $26.80M
YoY Change -29.22% -57.12% -57.12%
Cash & Equivalents $36.10M $24.85M $24.80M
Short-Term Investments $0.00 $2.000M $2.000M
Other Short-Term Assets $2.200M $2.800M $2.800M
YoY Change -31.25% -3.45% -3.45%
Inventory
Prepaid Expenses
Receivables $4.000K $108.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $38.34M $29.74M $29.70M
YoY Change -29.27% -54.51% -54.59%
LONG-TERM ASSETS
Property, Plant & Equipment $443.0K $523.0K $500.0K
YoY Change -35.89% -28.06% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $709.0K $523.0K $600.0K
YoY Change -4.32% -32.69% -14.29%
TOTAL ASSETS
Total Short-Term Assets $38.34M $29.74M $29.70M
Total Long-Term Assets $709.0K $523.0K $600.0K
Total Assets $39.05M $30.26M $30.30M
YoY Change -28.94% -54.25% -54.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.629M $1.096M $1.100M
YoY Change 215.09% 91.94% 83.33%
Accrued Expenses $3.055M $5.108M $5.100M
YoY Change 0.36% 32.06% 30.77%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000M $4.000M $4.000M
YoY Change 21.21% 73.91% 73.91%
Total Short-Term Liabilities $8.661M $10.18M $10.20M
YoY Change 26.25% 51.2% 52.24%
LONG-TERM LIABILITIES
Long-Term Debt $3.400M $4.300M $4.300M
YoY Change -52.11% -46.25% -46.25%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $3.400M $0.00 $4.300M
YoY Change 8192.68% -100.0% -46.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.661M $10.18M $10.20M
Total Long-Term Liabilities $3.400M $0.00 $4.300M
Total Liabilities $12.05M $14.51M $14.50M
YoY Change -13.89% -1.99% -2.03%
SHAREHOLDERS EQUITY
Retained Earnings -$176.2M -$168.2M
YoY Change 27.75% 33.15%
Common Stock $531.0K $23.00K
YoY Change 71.84% -92.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.00M $15.75M $15.80M
YoY Change
Total Liabilities & Shareholders Equity $39.05M $30.26M $30.30M
YoY Change -28.94% -54.25% -54.16%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$8.044M -$10.12M -$41.87M
YoY Change -30.83% -1.93% 28.04%
Depreciation, Depletion And Amortization $68.00K $70.00K $300.0K
YoY Change -6.85% 0.0% 0.0%
Cash From Operating Activities -$8.459M -$7.810M -$36.06M
YoY Change -28.37% -4.41% 34.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $84.00K
YoY Change -100.0% -100.0% -81.12%
Acquisitions
YoY Change
Other Investing Activities $2.000M $7.000M $0.00
YoY Change -171.94% -23.41% -100.0%
Cash From Investing Activities $2.001M $7.000M $28.23M
YoY Change -170.96% -22.99% -194.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.75M $2.283M
YoY Change 14214.49% -94.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $17.72M 800.0K $70.00K
YoY Change 8026.15% -8100.0% -99.83%
NET CHANGE
Cash From Operating Activities -$8.459M -7.810M -$36.06M
Cash From Investing Activities $2.001M 7.000M $28.23M
Cash From Financing Activities $17.72M 800.0K $70.00K
Net Change In Cash $11.26M -10.00K -$7.760M
YoY Change -178.11% -101.1% -47.69%
FREE CASH FLOW
Cash From Operating Activities -$8.459M -$7.810M -$36.06M
Capital Expenditures $0.00 $0.00 $84.00K
Free Cash Flow -$8.459M -$7.810M -$36.14M
YoY Change -28.59% -3.7% 32.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001590750
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53066099 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
56500000 USD
CY2019 dei Entity Registrant Name
EntityRegistrantName
Miragen Therapeutics, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2019 dei Trading Symbol
TradingSymbol
MGEN
CY2018Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
376000 USD
CY2019Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
284000 USD
CY2018Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
33000 USD
CY2019Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
1000 USD
CY2018Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
82000 USD
CY2019Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2018Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
1129000 USD
CY2019Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
2259000 USD
CY2018 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
55000 USD
CY2019 mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
3000 USD
CY2019Q4 mgen Capital Stock Shares Authorized
CapitalStockSharesAuthorized
105000000 shares
CY2018Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
500000 USD
CY2019Q4 mgen Contract With Customer Asset Incurred But Not Yet Billed
ContractWithCustomerAssetIncurredButNotYetBilled
300000 USD
CY2018 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2019 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2018Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
698000 USD
CY2019Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
605000 USD
CY2019 mgen Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
2 renewal_term
CY2018 mgen License Fee Expense Milestone Reached
LicenseFeeExpenseMilestoneReached
700000 USD
CY2019 mgen License Fee Expense Milestone Reached
LicenseFeeExpenseMilestoneReached
100000 USD
CY2018Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
367000 USD
CY2019Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
669000 USD
CY2018 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2019 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2016 mgen Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding
0.04
CY2019Q4 mgen Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding
SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding
2190922 shares
CY2019 mgen Tax Credit Carryforward Limitations On Use Amount
TaxCreditCarryforwardLimitationsOnUseAmount
4600000 USD
CY2019 mgen Tax Credit Carryforward Write Off
TaxCreditCarryforwardWriteOff
2800000 USD
CY2019 mgen Warrants Reclassification Of Warrant Liability From Equity
WarrantsReclassificationOfWarrantLiabilityFromEquity
18000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
571000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1096000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
108000 USD
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
416000 USD
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
432000 USD
CY2018 us-gaap Accretion Expense
AccretionExpense
376000 USD
CY2019 us-gaap Accretion Expense
AccretionExpense
340000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3868000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5108000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
246000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3970000 USD
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3576000 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3544000 shares
CY2018Q4 us-gaap Assets
Assets
66147000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000 USD
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
124000 USD
CY2019Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
66000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3090000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3348000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
177335000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183574000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3679000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3970000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3679000 USD
CY2019Q4 us-gaap Assets
Assets
30262000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
65370000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
29739000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29900000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2000000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29900000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
26800000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47441000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32606000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14835000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7760000 USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1826218 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30839463 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34861876 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30839463 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34861876 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
308000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
349000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32706000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6571000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41870000 USD
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
7667000 USD
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
69000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
32000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33100000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33136000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46200000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46240000 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24137000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32792000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10812000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
876000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1202000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
854000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
829000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33136000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46240000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
281000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
288000 USD
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.325
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.313
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.007
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.010
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.039
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.004
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.030
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.103
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.101
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1704000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
508000 USD
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000 USD
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M2D
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2990000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2668000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2696000 USD
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2695000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11049000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3357000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2857000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2898000 USD
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2534000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11646000 USD
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-335000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
525000 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1432000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
84000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
791000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1084000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-51000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-126000 USD
CY2018 us-gaap Interest And Debt Expense
InterestAndDebtExpense
873000 USD
CY2019 us-gaap Interest And Debt Expense
InterestAndDebtExpense
835000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
489000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
511000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
300000 USD
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2018Q4 us-gaap Liabilities
Liabilities
14803000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
14508000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66147000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30262000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6733000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10180000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
7667000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4000000 USD
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11624000 USD
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3667000 USD
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8004000 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4328000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41916000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29907000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28226000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26844000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36056000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4661000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-8714000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-9011000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-10317000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-32703000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11629000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-8896000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-11230000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-10118000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41873000 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4661000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8710000 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9021000 USD
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10314000 USD
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32703000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8887000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11238000 USD
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10121000 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41873000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1254000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
941000 USD
CY2018Q4 us-gaap Notes Payable
NotesPayable
10298000 USD
CY2019Q4 us-gaap Notes Payable
NotesPayable
8304000 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2294000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3976000 USD
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2018 us-gaap Operating Expenses
OperatingExpenses
41470000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
46440000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-33084000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-41979000 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
300000 USD
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
133000000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
121000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-3000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
66000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
147000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
140000 USD
CY2018Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
136000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
107000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
46000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000 USD
CY2019 us-gaap Payments For Restructuring
PaymentsForRestructuring
519000 USD
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3037000 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
77000 USD
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
62462000 USD
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32690000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
445000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000 USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2865000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2786000 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
44529000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2283000 USD
CY2018 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
242000 USD
CY2019 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
110000 USD
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33000000 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
61000000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
182000 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3817000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3871000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
727000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 USD
CY2018 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2333000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6413000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8375000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7399000 USD
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8234000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30421000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8751000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8599000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9027000 USD
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8417000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34794000 USD
CY2019 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
44 position
CY2019 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2019Q3 us-gaap Restructuring Charges
RestructuringCharges
1100000 USD
CY2019Q4 us-gaap Restructuring Charges
RestructuringCharges
900000 USD
CY2019 us-gaap Restructuring Charges
RestructuringCharges
2000000 USD
CY2019 us-gaap Restructuring Charges
RestructuringCharges
2034000 USD
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 USD
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
1515000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126296000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168200000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168169000 USD
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4784000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2182000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
944000 USD
CY2018Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
476000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8386000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
372000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2514000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
695000 USD
CY2019Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
880000 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4461000 USD
CY2019 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2557544 shares
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3679000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3970000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
3530773 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1394475 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4182404 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
29875000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
1999000 USD
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
242000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
182000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
87000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
38510000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
51344000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3000 USD
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
3000 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10600000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13100000 USD
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29600332 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31336409 shares
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">consolidated</font><font style="font-family:inherit;font-size:10pt;"> financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001590750-20-000021-index-headers.html Edgar Link pending
0001590750-20-000021-index.html Edgar Link pending
0001590750-20-000021.txt Edgar Link pending
0001590750-20-000021-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mgen-20191231.xml Edgar Link completed
mgen-20191231.xsd Edgar Link pending
mgen-20191231_cal.xml Edgar Link unprocessable
mgen-20191231_def.xml Edgar Link unprocessable
mgen-20191231_lab.xml Edgar Link unprocessable
mgen-20191231_pre.xml Edgar Link unprocessable
mgen-fy2019x10k.htm Edgar Link pending
mgen-fy2019xex1010.htm Edgar Link pending
mgen-fy2019xex10123.htm Edgar Link pending
mgen-fy2019xex211.htm Edgar Link pending
mgen-fy2019xex231.htm Edgar Link pending
mgen-fy2019xex311.htm Edgar Link pending
mgen-fy2019xex312.htm Edgar Link pending
mgen-fy2019xex321.htm Edgar Link pending
mgen-fy2019xex45.htm Edgar Link pending
pipeline.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending